Literature DB >> 25004197

The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis.

Gerald Jordan1, Danyael Lutgens, Ridha Joober, Martin Lepage, Srividya N Iyer, Ashok Malla.   

Abstract

OBJECTIVE: Functional recovery remains the primary goal following treatment of a psychotic disorder, especially after a first episode. Evidence regarding relative contributions of predictors of functional outcome, including symptoms and cognition, remains equivocal. The objective of the study was to determine the relative contribution of cognition, in particular verbal memory, and symptomatic remission to social and occupational functioning while controlling for established predictors of functioning in a large sample of patients presenting with a first episode of a schizophrenia spectrum or affective psychosis.
METHOD: Patients (aged 14-35 years) met DSM-IV criteria for a first episode of a schizophrenia spectrum or affective psychosis and had been admitted to the Prevention and Early Intervention Program for Psychoses, Montreal, Quebec, Canada, between 2003 and 2009 for treatment and follow-up for 2 years. Established predictors (duration of untreated psychosis, medication adherence, age at onset, substance use, premorbid adjustment), verbal memory, and length of positive and negative symptom remission were regressed on functioning (using the Strauss Carpenter Scale) at 1 (n = 208) and 2 (n = 159) years. Regressions were conducted with established predictors in the first step, followed by verbal memory and consecutive months of combined positive and negative symptom remission in the third step. Regressions were then repeated with length of positive and negative symptom remission, respectively.
RESULTS: Length of combined positive and negative symptom remission explained the most variance in functioning at 1 (R² adjusted = 0.35, F₉,₁₂₉ = 9.33, P < .001) and 2 (R² adjusted = 0.38, F₉,₉₇ = 8.21, P < .001) years, and verbal memory contributed only slightly to such outcome. While length of remission of negative symptoms was a stronger predictor of functioning than remission of positive symptoms at 1 year, length of positive symptom remission also made a large contribution at 2 years.
CONCLUSIONS: These results highlight the importance of achieving and maintaining remission of both negative and positive symptoms for longer periods in patients with a first episode of a psychotic disorder and the need for effective interventions to do so. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 25004197     DOI: 10.4088/JCP.13m08606

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  23 in total

1.  Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis.

Authors:  Ángel Del Rey-Mejías; David Fraguas; Covadonga M Díaz-Caneja; Laura Pina-Camacho; Josefina Castro-Fornieles; Inmaculada Baeza; Ana Espliego; Jessica Merchán-Naranjo; Ana González-Pinto; Elena de la Serna; Beatriz Payá; Montserrat Graell; Celso Arango; Mara Parellada
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-03-01       Impact factor: 4.785

Review 2.  Relapse risk assessment in early phase psychosis: the search for a reliable and valid tool.

Authors:  Phil Tibbo; Ashok Malla; Rahul Manchanda; Richard Williams; Ridha Joober
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

3.  Medication adherence in first episode psychosis: the role of pre-onset subthreshold symptoms.

Authors:  J-G Daneault; A Maraj; M Lepage; A Malla; N Schmitz; S N Iyer; R Joober; J L Shah
Journal:  Acta Psychiatr Scand       Date:  2019-04       Impact factor: 6.392

4.  Comparing three-year extension of early intervention service to regular care following two years of early intervention service in first-episode psychosis: a randomized single blind clinical trial.

Authors:  Ashok Malla; Ridha Joober; Srividya Iyer; Ross Norman; Norbert Schmitz; Thomas Brown; Danyael Lutgens; Eric Jarvis; Howard C Margolese; Nicola Casacalenda; Amal Abdel-Baki; Eric Latimer; Sally Mustafa; Sherezad Abadi
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

5.  Advances and challenges in early intervention in psychosis.

Authors:  Ashok Malla; Jai Shah; Shalini Lal
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

6.  Sex Differences in Verbal Memory Predict Functioning Through Negative Symptoms in Early Psychosis.

Authors:  Gabriella Buck; Katie M Lavigne; Carolina Makowski; Ridha Joober; Ashok Malla; Martin Lepage
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

Review 7.  Common Data Elements for National Institute of Mental Health-Funded Translational Early Psychosis Research.

Authors:  Dost Öngür; Cameron S Carter; Raquel E Gur; Diana Perkins; Akira Sawa; Larry J Seidman; Carol Tamminga; Wayne Huggins; Carol Hamilton
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-06-29

8.  Prefrontal Transcranial Direct Current Stimulation for Treatment of Schizophrenia With Predominant Negative Symptoms: A Double-Blind, Sham-Controlled Proof-of-Concept Study.

Authors:  Ulrich Palm; Daniel Keeser; Alkomiet Hasan; Michael J Kupka; Janusch Blautzik; Nina Sarubin; Filipa Kaymakanova; Ina Unger; Peter Falkai; Thomas Meindl; Birgit Ertl-Wagner; Frank Padberg
Journal:  Schizophr Bull       Date:  2016-04-20       Impact factor: 9.306

Review 9.  What Is the Place of Clozapine in the Treatment of Early Psychosis in Canada?

Authors:  Richard Williams; Ashok Malla; Marc-Andre Roy; Ridha Joober; Rahul Manchanda; Phil Tibbo; Nicola Banks; Ofer Agid
Journal:  Can J Psychiatry       Date:  2016-07-09       Impact factor: 4.356

10.  Sex Differences in Clinical and Functional Outcomes among Patients Treated in an Early Intervention Service for Psychotic Disorders: An Observational Study.

Authors:  Manish Dama; Franz Veru; Norbert Schmitz; Jai Shah; Srividya Iyer; Ridha Joober; Ashok Malla
Journal:  Can J Psychiatry       Date:  2019-06-12       Impact factor: 4.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.